NEW YORK, March 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0128202/HIV-Market-Forecast.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
This report explores key issues in HIV across the US and five major EU markets (France, Germany, Italy, Spain, and the UK). It contains an assessment of key HIV drugs, a discussion of HIV market dynamics, and a 10-year patient-based sales forecast.
OVERVIEW
Summary
OVERVIEW
This product contains forecasts for HIV drugs across the US and the five major EU markets (France, Germany, Italy, Spain, and the UK) from 2011 to 2021. It has been designed for delivery in an excel data pack format, but for more detail about this HIV forecast please see the accompanying Market and Product Forecast word document and PowerPoint executive presentation (HC00083-005).
The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.
Please select the data pack option from the download menu at the side of the page to access the model.
Introduction
Despite cost-containment efforts and an increasing threat of generic incursion, Datamonitor expects the HIV market in the US and five major EU markets (France, Germany, Italy, Spain, and the UK) to grow to $16,5bn in 2021. Major growth drivers are a continuously rising HIV prevalent population and the launch of new pipeline drugs, particularly of new single-tablet regimens (STRs).
Features and benefits
Research and analysis highlights
Key questions answered
Forecasting methodology
Volume and value forecast methodology
Price and compliance assumptions
Disclaimer
Companies mentioned
To order this report:
Pathology Industry: HIV Market Forecast
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article